Clinical efficacy and safety of oral versus subcutaneous administration of methotrexate in patients with rheumatoid arthritis;Skuteczność leczenia i wystȩpowanie działań niepoża̧danych w trakcie terapii metotreksatem podawanym doustnie i podskórnie chorym na reumatoidalne zapalenie stawów

Reumatologia

Volumn 46, Issue 6, 2008, Pages 322-329

  Świerkot, Jerzy ^a,c   Sokolik, Renata ^a   Gruszecka Marczyńska, Katarzyna ^a   Miȩdzybrodzki, Ryszard ^b   Szechiński, Jacek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Instytut Immunologii I Terapii Do wiadczalnej PAN we Wroc awiu   (Poland)

^c NONE   (Poland)

Author keywords

Methotrexat; Rheumatoid arthritis

Indexed keywords

EID: 60049090757     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Świerkot J, Szechiński J, Wiland P. Piȩcioletnia ocena kliniczna skuteczności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów. Pol Arch Med Wewn 2000; 103: 267-275.
2. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: second line drugs and prednisone. J Rheumatol 1992; 19: 1885-1894.
3. Schiff M, Keystone E, Cush J, et al. Discontinuation of DMARD therapy in patients with rheumatoid arthritis enrolled in RADIUS 1-rates, reason, and predictors of early drug withdrawal. RATreatment II. Program and abstracts of the American College of Rheumatology 67th Annual Scientific Meeting; October 23-28, Orlando, Florida Abstract S1708.
4. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450.
5. Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003; 42: 1009-1010.
6. Creinin MD, Krohn MA. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. Am J Obstet Gynecol 1997; 177: 1444-1449.
7. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-1849.
8. Kabisch S, Weigand T, Plischke H, Menninger H. Bioavailability of methotrexate (MTX) following different routes of application. Akt Rheumatol 2004; 29:197-200.
9. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-648.
10. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197-200.
11. Braun J, Kaestner P, Flaxenberg P, et al. The clinical efficacy and safety of subcutaneous (s.c.) versus oral application of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) - Results of a randomized, controlled, double-blind, multi-center study. Ann Rheum Dis 2006; 65 (supl II): 87.
12. Brandt A. Results of an observational study with parenteral MTX. Medac GmbH, Germany 2004.
13. Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol 2006; 35: 102-106.
14. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 423-426.
15. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-1382.
16. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who failed oral methotrexate. J Rheumatol 2004; 31: 179-182.